From: The Brazilian private pharmaceutical market after the first ten years of the generics law
Selected medicinesa | 2002 | 2006 | 2010 | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Branded generics | Generics | Generics + Branded generics | Branded generics | Generics | Generics + Branded generics | Branded generics | Generics | Generics + Branded generics | ||||||||||
N | % | N | % | N | % | N | % | N | % | N | % | N | % | N | % | N | % | |
Antibiotics | ||||||||||||||||||
Penicillins | 36 | 78.3 | 3 | 6.5 | 7 | 15.2 | 32 | 68.1 | 6 | 12.8 | 9 | 19.1 | 15 | 41.7 | 7 | 19.4 | 14 | 38.9 |
Fluoroquinolones | 29 | 85.3 | 2 | 5.9 | 3 | 8.8 | 36 | 69.2 | 9 | 17.3 | 7 | 13.5 | 22 | 47.8 | 12 | 26.1 | 12 | 26.1 |
Cephalosporins | 19 | 73.1 | 2 | 7.7 | 5 | 19.2 | 20 | 57.1 | 8 | 22.9 | 7 | 20 | 11 | 39.3 | 7 | 25 | 10 | 35.7 |
Macrolides | 29 | 82.9 | 1 | 2.9 | 5 | 14.3 | 31 | 72.1 | 2 | 4.7 | 10 | 23.3 | 23 | 57.5 | 7 | 17.5 | 10 | 25 |
Antidiabetics | ||||||||||||||||||
Glibenclamide | 11 | 91.7 | 1 | 8.3 | 0 | 0 | 15 | 71.4 | 5 | 23.8 | 1 | 4.8 | 12 | 57.1 | 8 | 38.1 | 1 | 4.8 |
Glimepiride | 2 | 100 | 0 | 0 | 0 | 0 | 9 | 69.2 | 3 | 23.1 | 1 | 7.7 | 6 | 35.3 | 9 | 52.9 | 2 | 11.8 |
Metformin | 4 | 66.7 | 1 | 16.7 | 1 | 16.7 | 13 | 56.5 | 9 | 39.1 | 1 | 4.3 | 13 | 41.9 | 15 | 48.4 | 3 | 9.7 |
Antihypertensives | ||||||||||||||||||
Methyldopa | 12 | 92.3 | 1 | 7.7 | 0 | 0 | 13 | 76.5 | 2 | 11.8 | 2 | 11.8 | 7 | 63.6 | 2 | 18.2 | 2 | 18.2 |
Diuretics | 20 | 90.9 | 1 | 4.5 | 1 | 4.5 | 27 | 77.1 | 5 | 14.3 | 3 | 8.6 | 22 | 68.8 | 6 | 18.8 | 4 | 12.5 |
Betablockers | 13 | 76.5 | 2 | 11.8 | 2 | 11.8 | 17 | 60.7 | 6 | 21.4 | 5 | 17.9 | 15 | 48.4 | 9 | 29 | 7 | 22.6 |
Calcium antagonists | 18 | 81.8 | 2 | 9.1 | 2 | 9.1 | 24 | 63.2 | 8 | 21.1 | 6 | 15.8 | 16 | 48.5 | 11 | 33.3 | 6 | 18.2 |
ACE inhibitorsd | 26 | 78.8 | 3 | 9.1 | 4 | 12.1 | 37 | 71.2 | 8 | 15.4 | 7 | 13.5 | 33 | 62.3 | 12 | 22.6 | 8 | 15.1 |